Novartis Aktie

92,82 EUR -0,74 EUR -0,79 %

11:38:24

L&S

86,00 CHF -1,04 CHF -1,19 %

11:51:09

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.182,80 Mrd. EUR

KGV13,21Div. Rendite3,89%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

08.06.23PR NewswireKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

08.06.23GlobeNewswireSandoz presents compelling investment proposition as standalone company at Capital Markets Day

08.06.23Dow JonesPress Release: Novartis: Sandoz presents compelling investment proposition as standalone company at Capital Markets Day

02.06.23GlobeNewswireNovartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

02.06.23Dow JonesPress Release: Novartis Kisqali(R) significantly -3-

02.06.23Dow JonesPress Release: Novartis Kisqali(R) significantly -2-

02.06.23Dow JonesPress Release: Novartis Kisqali(R) significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinic...

01.06.23GlobeNewswireSandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company

01.06.23Dow JonesPress Release: Novartis: Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company

25.05.23GlobeNewswireSandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA

25.05.23Dow JonesPress Release: Novartis: Sandoz Marketing -2-

25.05.23Dow JonesPress Release: Novartis: Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA

15.05.23GlobeNewswireNew Sandoz Board of Directors appointed

15.05.23Dow JonesPress Release: Novartis: New Sandoz Board of -2-

15.05.23Dow JonesPress Release: Novartis: New Sandoz Board of Directors appointed

11.05.23GlobeNewswireNovartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

09.05.23GlobeNewswireSandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

04.05.23GlobeNewswireSandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines

04.05.23Dow JonesPress Release: Novartis: Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines

26.04.23GlobeNewswireNovartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

26.04.23Dow JonesPress Release: Novartis Cosentyx(R) gains -2-

26.04.23Dow JonesPress Release: Novartis Cosentyx(R) gains positive CHMP opinion for hidradenitis suppurativa

26.04.23GlobeNewswireNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO

26.04.23Dow JonesPress Release: Novartis to present new data -2-

26.04.23GlobeNewswireNovartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

26.04.23Dow JonesPress Release: Novartis Phase III APPOINT-PNH -3-

26.04.23Dow JonesPress Release: Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to tr...

25.04.23GlobeNewswireNovartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

25.04.23Dow JonesPress Release: Novartis delivers strong sales -3-

25.04.23Dow JonesPress Release: Novartis delivers strong sales -2-

25.04.23Dow JonesPress Release: Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

20.04.23GlobeNewswireNovartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

20.04.23Dow JonesPress Release: Novartis presents new five-year -2-

20.04.23Dow JonesPress Release: Novartis presents new five-year data on disability outcomes and safety of Kesimpta(R) (ofatumumab) in people living with relapsing multiple sc...

03.04.23GlobeNewswireSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

03.04.23Dow JonesPress Release: Novartis: Sandoz receives approval by European Commission for Hyrimoz(R) (adalimumab) high-concentration formulation

31.03.23GlobeNewswireNovartis Entresto receives positive CHMP opinion for pediatric heart failure

31.03.23Dow JonesPress Release: Novartis Entresto receives -2-

31.03.23Dow JonesPress Release: Novartis Entresto receives positive CHMP opinion for pediatric heart failure

27.03.23GlobeNewswireNovartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.